Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 3, 2025 • 8:31 AM ET

Date/Time Source News Release
05/19/2025 07:00 AM EDT PR Newswire Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
05/14/2025 04:05 PM EDT PR Newswire Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
05/01/2025 07:00 AM EDT PR Newswire Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
03/20/2025 05:56 PM EDT PR Newswire Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
03/12/2025 05:08 PM EDT PR Newswire Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
03/11/2025 07:00 AM EDT PR Newswire Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit
12/19/2024 07:00 AM EST PR Newswire Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
11/19/2024 07:00 AM EST PR Newswire Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
11/13/2024 04:05 PM EST PR Newswire Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
11/12/2024 07:00 AM EST PR Newswire Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
Page

Additional News

As of June 3, 2025 • 8:31 AM ET

Date/Time Source News Release
05/21/2025 09:50 AM EDT Zacks ARMP Soars 72% in a Month Following Infectious Disease Study Success
05/14/2025 05:45 PM EDT Zacks Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
05/14/2025 05:37 PM EDT SeekingAlpha Armata Pharmaceuticals GAAP EPS of -$0.20 beats by $0.18, revenue of $0.49M misses by $0.89M
05/14/2025 09:10 AM EDT Zacks ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
05/12/2025 05:55 PM EDT Zacks Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
05/08/2025 07:10 AM EDT Zacks New Strong Sell Stocks for May 8th
04/28/2025 04:53 AM EDT Zacks New Strong Sell Stocks for April 28th
04/24/2025 06:25 AM EDT Zacks New Strong Sell Stocks for April 24th
04/09/2025 05:24 AM EDT Zacks New Strong Sell Stocks for April 9th
03/21/2025 01:12 AM EDT SeekingAlpha Armata Pharmaceuticals GAAP EPS of -$0.23, revenue of $1.2M
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.